Fig. 1From: Novel applications of molecular imaging to guide breast cancer therapyThis patient with ER-positive breast cancer started a new endocrine therapy. Her FDG-avid osseous lesions did not demonstrate a decrease in FDG uptake to indicate a metabolic response at 4 weeks and 12 weeks. The patient progressed relatively quickly, in just over 100 daysBack to article page